Lung cancer remains the leading cause of cancer-related mortality worldwide. Genetic alterations such as KRAS mutations, EGFR mutation, overexpression, and TP53 mutations are well-known drivers of tumorigenesis in lung cancer. Despite advancements in targeted therapies and immunotherapies, the disease often presents at advanced stages and exhibits significant resistance mechanisms, underscoring the need for deeper molecular insights and novel therapeutic strategies.